MARKET

ICCC

ICCC

ImmuCell
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.75
-0.02
-0.35%
Opening 12:36 10/22 EDT
OPEN
5.85
PREV CLOSE
5.77
HIGH
5.86
LOW
5.64
VOLUME
8.66K
TURNOVER
--
52 WEEK HIGH
8.13
52 WEEK LOW
3.700
MARKET CAP
41.47M
P/E (TTM)
-24.3747
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
How Much Does ImmuCell's (NASDAQ:ICCC) CEO Make?
This article will reflect on the compensation paid to Michael Brigham who has served as CEO of ImmuCell Corporation...
Simply Wall St. · 3d ago
ImmuCell reports Q3 preliminary sales
ImmuCell (ICCC) reports Q3 total product sales increased by 25% to $3.7M vs. $3.27M consensus.“We reduced the backlog of orders that was worth ~$1.4M as of March 31, 2020 and
Seekingalpha · 10/06 12:05
ImmuCell Announces Preliminary, Unaudited Sales Results for the Quarter Ended September 30, 2020
PORTLAND, Maine, Oct. 06, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef calves,
GlobeNewswire · 10/06 12:00
ImmuCell Q2 EPS $(0.11) Misses $(0.10) Estimate, Sales $2.97M Up From $2.71M YoY
ImmuCell (NASDAQ:ICCC) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.10) by 10 percent. This is a 22.22 percent decrease over losses of $(0.09) per share from the same
Benzinga · 08/12 20:11
The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 08/12 11:29
ImmuCell to Announce Unaudited Financial Results for Second Quarter of 2020
Conference Call Scheduled for Thursday, August 13, 2020 at 9:00 AM ETPORTLAND, Maine, Aug. 06, 2020 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets s
GlobeNewswire · 08/06 12:00
ImmuCell sees Q2 product sales as high as $3M
Seeking Alpha - Article · 07/07 13:45
ImmuCell Announces Preliminary, Unaudited Sales Results for the Second Quarter Ended June 30, 2020
GlobeNewswire · 07/07 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ICCC. Analyze the recent business situations of ImmuCell through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ICCC stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 33
Institutional Holdings: 1.10M
% Owned: 15.26%
Shares Outstanding: 7.21M
TypeInstitutionsShares
Increased
5
29.83K
New
9
-272.20K
Decreased
4
99.23K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
+0.04%
Key Executives
Chairman/Director
David Tomsche
President/Chief Executive Officer/Treasurer/Secretary/Director
Michael Brigham
Chief Scientific Officer/Vice President
Joseph Crabb
Vice President/Director of Sales/Director of Marketing/Director
Bobbi Brockmann
Vice President
Elizabeth Williams
Independent Director
David Cunningham
Independent Director
Steven Rosgen
Independent Director
Jonathan Rothschild
Independent Director
Paul Wainman
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ICCC
ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Company's lead product, First Defense, is manufactured from cows' colostrum utilizing its vaccine and milk protein purification technologies. Its Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. It also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. Its product development initiative is Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of ImmuCell Corporation stock information, including NASDAQ:ICCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICCC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICCC stock methods without spending real money on the virtual paper trading platform.